National Lung Cancer Partnership, Medical Centers Collaborate to Provide Tumor Testing

The National Lung Cancer Partnership is collaborating with 14 top cancer centers across the country to sustain the Lung Cancer Mutation Consortium, the largest-ever effort to promote molecular tumor testing for lung cancer patients.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
"Working with the LCMC represents an opportunity for the Partnership to directly improve patient care,” said Regina Vidaver, Ph.D., the Partnership’s executive director.

MADISON, Wis. (PRWEB) May 02, 2012

The National Lung Cancer Partnership is collaborating with 14 top cancer centers coast to coast to sustain the Lung Cancer Mutation Consortium, the largest-ever effort to promote molecular tumor testing for lung cancer patients. The identification of specific genetic mutations in lung tumors is revolutionizing the treatment of lung cancer, which takes the lives of 160,000 people in the U.S. every year, more than any other type of cancer.

The primary goal of the LCMC is to analyze the frequency and characteristics of genetic mutations in lung cancer and match patients to specific treatment options with that information. The LCMC was initiated in 2009 through a $5.3 million grant provided by the American Recovery and Reinvestment Act. With the expiration of these funds, the Partnership is assuming a leadership role in managing private sector funds that will allow the LCMC to continue its critical work, enabling detection of new mutations and facilitating access to associated targeted therapies.

To date, the cancer centers in the LCMC have enrolled and collected tumor samples from more than 1,000 patients with advanced adenocarcinoma, the most common form of lung cancer. According to research based on the first 830 patients enrolled, genetic mutations were found in approximately 60 percent of lung tumors tested.

“Everything we do is for the patient, from funding lung cancer research to providing educational materials. Working with the LCMC represents an opportunity for the Partnership to directly improve patient care,” said Regina Vidaver, Ph.D., the Partnership’s executive director. “The LCMC aims to make tumor testing widely available to lung cancer patients and promote personalized medicine, providing the right treatment to the right patient at the right time.”

Patients who participate in the LCMC study will have their tumors tested and analyzed for a number of mutations. The results will be used to provide each patient with tailored treatments, including those available through clinical trials. The information collected from patient’s tumors is being used to create a unique national data set that will help determine the frequency of certain mutations and promote opportunities for research into new treatment options. The ultimate goal is to improve the survival of people with lung cancer, which has inched up in the last several years from 15 to 17 percent five years after diagnosis.

LCMC patient enrollment is expected to resume in August. Until then, lung cancer patients are encouraged to contact their local LCMC member institutions to determine if they are candidates for the study. For more information about the LCMC and to download a brochure about molecular tumor testing, visit http://www.NationalLungCancerParnership.org.

The LCMC is coordinated by a team of researchers at the University of Colorado Cancer Center, Denver. Other participating centers include: Dana-Farber/Brigham and Women’s Cancer Center, Boston; Winship Cancer Institute of Emory University, Atlanta; Moffitt Cancer Center, Tampa, Fla.; Johns Hopkins/Sidney Kimmel Comprehensive Cancer Center, Baltimore; the University of Texas MD Anderson Cancer Center, Houston; Massachusetts General Hospital Cancer Center, Boston; Memorial Sloan-Kettering Cancer Center, New York; UCLA Jonsson Comprehensive Cancer Center, Los Angeles; University of Pittsburgh Cancer Institute, Pittsburg; the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, Dallas; Vanderbilt-Ingram Cancer Center, Nashville, Tenn.; and Hollings Cancer Center at the Medical University of South Carolina, Charleston, S.C.

The LCMC is currently supported by funding from Pfizer Inc. and Genentech, a Member of the Roche Group.

# # #
The National Lung Cancer Partnership
The National Lung Cancer Partnership is a 501(c)(3) non-profit organization made up of leading doctors, researchers, patient advocates, and lung cancer survivors dedicated to raising public awareness of the disease and generating funding for lung cancer research. For more information, please visit http://www.NationalLungCancerPartnership.org.

The Lung Cancer Mutation Consortium
The Lung Cancer Mutation Consortium (LCMC) represents the largest national initiative to prospectively examine mutations in non-small cell lung cancers through14 leading cancer centers across the country. Our primary goal is to identify frequencies, characteristics, and therapeutic options for genetic mutations found specifically in lung cancer. The LCMC is coordinated by a team of researchers at the University of Colorado Cancer Center. For more information, please visit http://www.GoLCMC.com.


Contact

Attachments

Lung Cancer Molecular Testing Brochure Lung Cancer Molecular Testing Brochure

Everything you need to know about lung cancer molecular testing